The Medicines Company

                   

Cleviprex(TM) Reduces And Controls Acutely Elevated Blood Pressure In Elderly Patients, According...

medicalnewstoday.com     Jun 2, 2008          

The Medicines Company (NASDAQ: MDCO) announced that its investigational agent, CleviprexTM (clevidipine butyrate) injectable emulsion was well tolerated in elderly patients and rapidly achieved and maintained blood pressure control...                    

comments

                   

RealPennies.com: Turning Pennies into dollars: (Other OTC: MIHS), (AMEX: AQQ), (NASDAQ: IVAN),...

tmcnet.com     Jun 2, 2008          

Are you a public company looking for exposure? Robert Friedland, Deputy Chairman of Ivanhoe Energy Inc. (TSX: IE; NASDAQ: IVAN), announced that the company has signed a preliminary agreement with Talisman Energy Canada (Talisman) to...                    

comments

Tongjitang Chinese Medicines Company posts figures for first quarter 2008

m2.com     Jun 2, 2008          

Tongjitang Chinese Medicines Company (NYSE:TCM), a speciality pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernised traditional Chinese medicine in China, reported on 30 May its...                    

comments

Tongjitang Chinese Medicines Company Announces First Quarter 2008 Financial Results (Business Wire)

yahoo.com     May 30, 2008   4 related          

SHENZHEN, China----Tongjitang Chinese Medicines Company , a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today...                    

comments

                   

InvestSource Inc.: Medical Institutional Services Holdings Signs with Q-med

tmcnet.com     May 30, 2008          

InvestSource Inc.: Medical Institutional Services Holdings Signs with Q-med ... Stocks in the News: Medical Institutional Services Holdings, Inc. (Other OTC: MIHS), American Spectrum Realty, Inc. (AMEX: AQQ), Ivanhoe Energy Inc. (NASDAQ: IVAN), The Medicines Company...                    

comments

                   

Cleviprex(TM) Reduces and Controls Acutely Elevated Blood Pressure in Elderly Patients, According...

yahoo.com     May 29, 2008   2 related          

WASHINGTON----The Medicines Company today announced that its investigational agent, CleviprexTM injectable emulsion was well tolerated in elderly patients and rapidly achieved and maintained blood pressure control in patients presenting to the emergency department or intensive care unit with...                    

comments

                   

The Hampshire Companies Awarded NJ-NAIOP's Coveted Economic Impact Deal of the Year

prweb.com     May 29, 2008   2 related          

The Hampshire Companies, a full service, private real estate investment fund manager with equity in assets valued at over $2 billion, has been awarded the highly coveted Economic Impact Deal of the Year Award from the New Jersey Chapter of National Association of Industrial and Office Properties...                    

comments

Medicines Co. Shares Fall after FDA Rejects Angiomax

ibtimes.com     May 29, 2008   7 related          

The Medicines Company said on a press release on Wednesday that it received a not approvable letter from U.S. regulators on a supplemental New Drug Application for an additional dosing regimen for Angiomax in the treatment of acute coronary syndromes.                    

comments

                   

Pre-Open Movers 5/28: Ralph Lauren (RL) Higher After Results/Buyback; KeyCorp (KEY) Sinks After...

streetinsider.com     May 28, 2008   7 related          

StreetInsider.com Pre-Open Movers: Forward Industries, Inc. (Nasdaq: FORD) 14.6% HIGHER; entered into a new, non-exclusive license agreement with Motorola Inc. (NYSE: MOT) to distribute Motorola branded products to customers in the United States, Canada, and Europe, through March 31, 2009....                    

comments

The Medicines Company Receives FDA Review Letter for Angiomax Supplemental Filing (Business Wire)

yahoo.com     May 28, 2008   1 related          

PARSIPPANY, N.J.----The Medicines Company announced receipt of a not approvable letter from the U.S. Food and Drug Administration on a supplemental New Drug Application for an additional dosing regimen for Angiomax® in the treatment of acute coronary syndromes initiated in the emergency department.                    

comments